Related Experiment Video
Updated: Mar 6, 2026
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
PARP inhibitors: Synthetic lethality in the clinic
Christopher J Lord1, Alan Ashworth2
1The Cancer Research UK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. chris.lord@icr.ac.uk alan.ashworth@ucsf.edu.
Abstract:
PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a century ago. Tumors arising in patients who carry germline mutations in either BRCA1 or BRCA2 are sensitive to PARPi because they have a specific type of DNA repair defect. PARPi also show promising activity in more common cancers that share this repair defect. However, as with other targeted therapies, resistance to PARPi arises in advanced disease. In addition, determining the optimal use of PARPi within drug combination approaches has been challenging. Nevertheless, the preclinical discovery of PARPi synthetic lethality and the route to clinical approval provide interesting lessons for the development of other therapies. Here, we discuss current knowledge of PARP inhibitors and potential ways to maximize their clinical effectiveness.
Insights
Poly(ADP-ribose) polymerase inhibitors (PARPi) exploit synthetic lethality in BRCA-mutated cancers. Research explores overcoming PARPi resistance and optimizing combination therapies for broader cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- PARP inhibitors (PARPi) represent a novel cancer therapy class.
- They leverage the concept of synthetic lethality, targeting tumors with specific DNA repair defects, notably in BRCA1/BRCA2 mutations.
- PARPi demonstrate efficacy in cancers beyond those with BRCA mutations, provided they share similar DNA repair deficiencies.
Purpose of the Study:
- To review the current understanding of PARP inhibitors.
- To explore strategies for enhancing their clinical effectiveness.
- To discuss challenges in PARPi therapy, including resistance and optimal combination approaches.
Main Methods:
- Review of preclinical and clinical research on PARP inhibitors.
- Analysis of synthetic lethality principles in cancer genetics.
- Discussion of drug resistance mechanisms and combination therapy strategies.
Main Results:
- PARPi are effective in BRCA-mutated cancers due to synthetic lethality.
- PARPi show promise in other cancers with homologous recombination DNA repair defects.
- Resistance to PARPi is a significant challenge in advanced disease.
Conclusions:
- The development of PARPi offers valuable insights for other targeted cancer therapies.
- Further research is needed to overcome resistance and optimize combination treatments.
- Maximizing PARPi clinical effectiveness requires a comprehensive understanding of their mechanisms and resistance pathways.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:37Restarting Stalled Replication Forks